PT2237783E - Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib - Google Patents
Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib Download PDFInfo
- Publication number
- PT2237783E PT2237783E PT97042568T PT09704256T PT2237783E PT 2237783 E PT2237783 E PT 2237783E PT 97042568 T PT97042568 T PT 97042568T PT 09704256 T PT09704256 T PT 09704256T PT 2237783 E PT2237783 E PT 2237783E
- Authority
- PT
- Portugal
- Prior art keywords
- imatinib
- pharmaceutically acceptable
- acceptable salt
- treatment
- kit
- Prior art date
Links
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title claims description 57
- 239000005517 L01XE01 - Imatinib Substances 0.000 title claims description 52
- 229960002411 imatinib Drugs 0.000 title claims description 52
- 238000011282 treatment Methods 0.000 title claims description 16
- 201000010099 disease Diseases 0.000 title description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 18
- 238000000034 method Methods 0.000 title description 17
- 230000001404 mediated effect Effects 0.000 title description 13
- 230000002062 proliferating effect Effects 0.000 title description 12
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 title 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 26
- 230000035772 mutation Effects 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical class CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 11
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 201000008736 Systemic mastocytosis Diseases 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000007033 Dysgerminoma Diseases 0.000 description 2
- 208000035268 Mast Cell Activation disease Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000008217 Aggressive systemic mastocytosis Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2294508P | 2008-01-23 | 2008-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2237783E true PT2237783E (pt) | 2014-12-23 |
Family
ID=40435094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97042568T PT2237783E (pt) | 2008-01-23 | 2009-01-21 | Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20100298338A1 (enExample) |
| EP (1) | EP2237783B1 (enExample) |
| JP (2) | JP5936821B2 (enExample) |
| KR (1) | KR101579993B1 (enExample) |
| CN (1) | CN101951910B (enExample) |
| AU (1) | AU2009206566A1 (enExample) |
| BR (1) | BRPI0906504A2 (enExample) |
| CA (1) | CA2712087A1 (enExample) |
| ES (1) | ES2526537T3 (enExample) |
| MX (1) | MX2010008103A (enExample) |
| PL (1) | PL2237783T3 (enExample) |
| PT (1) | PT2237783E (enExample) |
| RU (1) | RU2537223C2 (enExample) |
| WO (1) | WO2009094360A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2753391C1 (ru) * | 2020-09-29 | 2021-08-13 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0127922D0 (en) * | 2001-11-21 | 2002-01-16 | Novartis Ag | Organic compounds |
| SI1686997T1 (sl) * | 2003-11-18 | 2009-08-31 | Novartis Ag | Inhibitorji mutantne oblike KIT |
| US7329495B2 (en) * | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| EP2251042A3 (en) * | 2006-09-22 | 2012-05-02 | Novartis AG | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
| CA2668828A1 (en) | 2006-11-07 | 2008-05-29 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
-
2009
- 2009-01-21 EP EP09704256.8A patent/EP2237783B1/en not_active Revoked
- 2009-01-21 US US12/863,627 patent/US20100298338A1/en not_active Abandoned
- 2009-01-21 MX MX2010008103A patent/MX2010008103A/es active IP Right Grant
- 2009-01-21 BR BRPI0906504-0A patent/BRPI0906504A2/pt not_active IP Right Cessation
- 2009-01-21 PL PL09704256T patent/PL2237783T3/pl unknown
- 2009-01-21 CN CN2009801027282A patent/CN101951910B/zh not_active Expired - Fee Related
- 2009-01-21 JP JP2010544393A patent/JP5936821B2/ja not_active Expired - Fee Related
- 2009-01-21 CA CA2712087A patent/CA2712087A1/en not_active Abandoned
- 2009-01-21 KR KR1020107018386A patent/KR101579993B1/ko not_active Expired - Fee Related
- 2009-01-21 RU RU2010134916/15A patent/RU2537223C2/ru not_active IP Right Cessation
- 2009-01-21 AU AU2009206566A patent/AU2009206566A1/en not_active Abandoned
- 2009-01-21 PT PT97042568T patent/PT2237783E/pt unknown
- 2009-01-21 ES ES09704256.8T patent/ES2526537T3/es active Active
- 2009-01-21 WO PCT/US2009/031510 patent/WO2009094360A1/en not_active Ceased
-
2013
- 2013-12-18 JP JP2013261728A patent/JP5881671B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-27 US US14/924,207 patent/US20160045501A1/en not_active Abandoned
-
2016
- 2016-10-19 US US15/297,372 patent/US9763944B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2237783B1 (en) | 2014-11-19 |
| PL2237783T3 (pl) | 2015-04-30 |
| AU2009206566A1 (en) | 2009-07-30 |
| CA2712087A1 (en) | 2009-07-30 |
| US20170035757A1 (en) | 2017-02-09 |
| CN101951910A (zh) | 2011-01-19 |
| WO2009094360A1 (en) | 2009-07-30 |
| JP2011510086A (ja) | 2011-03-31 |
| JP2014094946A (ja) | 2014-05-22 |
| RU2537223C2 (ru) | 2014-12-27 |
| US9763944B2 (en) | 2017-09-19 |
| RU2010134916A (ru) | 2012-02-27 |
| ES2526537T3 (es) | 2015-01-13 |
| EP2237783A1 (en) | 2010-10-13 |
| JP5881671B2 (ja) | 2016-03-09 |
| US20100298338A1 (en) | 2010-11-25 |
| KR20100105778A (ko) | 2010-09-29 |
| JP5936821B2 (ja) | 2016-06-22 |
| CN101951910B (zh) | 2013-07-17 |
| KR101579993B1 (ko) | 2015-12-23 |
| MX2010008103A (es) | 2010-08-23 |
| US20160045501A1 (en) | 2016-02-18 |
| BRPI0906504A2 (pt) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2558095T3 (en) | ORGANIC RELATIONSHIP FOR USE IN TREATMENT OF DELIVERY CANCER | |
| US20210161888A1 (en) | Composition and method of treating cancer associated with egfr mutation | |
| BR112015023483B1 (pt) | Uso de um inibidor de b-raf e um inibidor de mek ½” | |
| US20230330091A1 (en) | Method of Adjuvant Cancer Treatment | |
| TW201127383A (en) | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity | |
| TW201217361A (en) | Method of treating abnormal cell growth | |
| CN118647379A (zh) | 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 | |
| ES2738864T3 (es) | Combinaciones de inhibidores de MEK, EGFR y ERBB2 en el tratamiento del cáncer de pulmón causado por un mutante de KRAS | |
| BR112021015908A2 (pt) | Composição antitumoral | |
| PT2237783E (pt) | Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib | |
| AU2013201993B2 (en) | Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib | |
| JP4522261B2 (ja) | ブドウ膜黒色腫の処置 | |
| RU2774612C2 (ru) | Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk | |
| KR20240164549A (ko) | 암 치료를 위한 metap2 억제제를 포함하는 조합 | |
| CN117897158A (zh) | Erk1/2和shp2抑制剂组合疗法 | |
| US20060167006A1 (en) | Method of treatment | |
| US20030191131A1 (en) | Use of organic compounds | |
| CN1671389A (zh) | 用于治疗间变性甲状腺癌的4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－基)嘧啶－2－基氨基)苯基]－苯甲酰胺 | |
| BR112019005046B1 (pt) | Combinação farmacêutica, seu uso, composição farmacêutica, usos de um inibidor de craf e de um inibidor de erk, e kit | |
| Gupta et al. | Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic | |
| JP2019182764A (ja) | 慢性脂肪性疾患の予防および治療用医薬 | |
| HK1206642B (en) | Method of adjuvant cancer treatment |